✦ LIBER ✦

Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens

✍ Scribed by Kuemmerle-Deschner, Jasmin B; Wittkowski, Helmut; Tyrrell, Pascal N; Koetter, Ina; Lohse, Peter; Ummenhofer, Katharina; Reess, Fabian; Hansmann, Sandra; Koitschev, Assen; Deuter, Christoph; Bialkowski, Anja; Foell, Dirk; Benseler, Susanne M

Book ID: 121630090
Publisher: BioMed Central
Year: 2013
Tongue: English
Weight: 206 KB
Volume: 15
Category: Article
ISSN: 1478-6354
DOI: 10.1186/ar4237

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Durability of Response to Rilonacept (IL

Durability of Response to Rilonacept (IL-1 Trap) in a Phase 3 Study of Patients with Cryopyrin-Associated Periodic Syndromes (CAPS): Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS)

✍ HOFFMAN, H; AMAR, N; CARTWRIGHT, R; KIVITZ, A; BELOMESTNOV, P; MELLIS, S; WEINST 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Trospium chloride once-daily extended re

Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials

✍ D. R. Staskin; M. T. Rosenberg; P. K. Sand; N. R. Zinner; R. R. Dmochowski 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB

13 A 12-WEEK INTERFERON-FREE REGIMEN OF

13 A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS

✍ E. Lawitz; F. Poordad; K.V. Kowdley; D. Jensen; D.E. Cohen; S. Siggelkow; K. Wik 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 105 KB

756 Two Dose-Equivalent, 21-Days, Subcut

756 Two Dose-Equivalent, 21-Days, Subcutaneous (S.C.), Glucagon-Like Peptide 2 (GLP-2) Dosing Regimens, 1.0 Mg Continuously Versus 0.33 Mg Three Time Daily (tid), in the Treatment of Short Bowel Syndrome (SBS) Patients

✍ Palle B. Jeppesen; Ida B. Gottschalck; Jens J. Holst; Per B. Mortensen; Bolette 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 104 KB

P093 TWO DOSE-EQUIVALENT, 21-DAYS, SUBCU

P093 TWO DOSE-EQUIVALENT, 21-DAYS, SUBCUTANEOUS (S.C.), GLUCAGON-LIKE PEPTIDE 2 (GLP-2) DOSING REGIMENS, 1.0 MG CONTINUOUSLY VERSUS 0.33 MG THREE TIME DAILY (TID), IN THE TREATMENT OF SHORT BOWEL SYNDROME (SBS) PATIENTS

✍ P.B. Jeppesen; I.B. Gottschalck; J.J. Holst; B. Hartman; P.B. Mortensen 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

M1824a Two Dose-Equivalent, 56-Days, Sub

M1824a Two Dose-Equivalent, 56-Days, Subcutaneous (s.c.), Glucagon-Like Peptide 2 (GLP-2) Regimens, 1.6 Mg Once Daily (OD) Versus 0.4 Mg Four Times Daily (QID), in the Treatment of Short Bowel Syndrome (SBS) Patients

✍ Jeppesen, Palle B.; Gottschalck, Ida B.; Holst, Jens J.; Mortensen, Per B. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 137 KB